AKT1 and Insulin resistance: Many PP2A agonists inactivate AKT (Gutierrez et al, 2014; Suman et al, 2016; Tohmé et al, 2019; Tsuji et al, 2021) which makes them ill‐suited for use as obesity therapies as they would cause insulin resistance.